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Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with
denosumab in postmenopausal women with low bone mass.
Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover
markers as well as safety with 6 yr of denosumab treatment.
Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging
phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous
denosumab treatment.
Setting: This multicenter study was conducted at 23 U.S. centers.
Patients: Of the 262 subjects who completed the parent study, 200 enrolled in the study extension
and 178 (89%) completed the first 2 yr.
Intervention: All subjects received denosumab 60 mg sc every 6 months.
Main Outcome Measures: We evaluated BMD at the lumbar spine, total hip, femoral neck, and one
third radius; biochemical markers of bone turnover; and safety, reported as adverse events.
Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains
in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sus-
tained over the course of continuous treatment. Independent of past treatment and discontinu-
ation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD
and bone turnover markers. The safety profile of denosumab did not change over time.
Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treat-
ment in postmenopausal women with low bone mass. (J Clin Endocrinol Metab 96: 394–402, 2011)
At menopause, with reduction in estrogen levels, sub-stantial bone loss commences with accelerated bone
turnover. Resultant microarchitectural deterioration, in-
cluding perforation and loss of trabeculae in cancellous
bone, cortical thinning, and increased porosity, leads to an
increase in bone fragility and susceptibility to fracture (1,
2). Based on this pathophysiology and the burden of dis-
ease, the aim of pharmacological intervention in the treat-
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ment of osteoporosis is to decrease fracture risk. Ther-
apeutics within several classes have been approved for
the treatment of osteoporosis and may be categorized by
their ability to either decrease bone resorption (antire-
sorptive therapies) or increase bone formation (ana-
bolic therapies). Evaluation of antifracture efficacy
with antiresorptive therapies in randomized, controlled
trials and metaanalyses has found associations between
the degree of reduction in bone turnover or the increase
in bone mineral density (BMD) with the resultant de-
crease in fracture risk (3–9). Despite the availability of
current osteoporosis agents, unmet needs in the treat-
ment of osteoporosis include poor compliance and per-
sistence with therapy, intolerance to therapy, and com-
plexities of administration.
Denosumab (Prolia) is a fully human monoclonal an-
tibody to receptor activator of nuclear factor-B ligand
(RANKL), an osteoblast-derived glycoprotein. Deno-
sumab is an IgG2 with high affinity (Kd  3  10
12
M)
for RANKL (10). Denosumab binds RANKL, prevent-
ing the activation of osteoclast-receptor RANK, and
inhibiting the formation, activation, and survival of os-
teoclasts. This results in a reduction in bone resorption
and an increase in cortical and trabecular bone mass,
volume, and strength (11). Denosumab is a highly spe-
cific molecule because it does not bind to other members
of the TNF family, including TNF, TNF, TNF-re-
lated apoptosis-inducing ligand (TRAIL), or CD40 li-
gand. As a result of its unique and specific mechanism
of action, denosumab is available for treatment of os-
teoporosis and has been approved in some countries as
a therapy for bone loss associated with hormone abla-
tion therapy. In clinical trials, denosumab has been
shown to decrease the risk for vertebral, nonvertebral,
and hip fractures in postmenopausal women with os-
teoporosis (12) and risk for new vertebral fractures in
men with nonmetastatic prostate cancer receiving an-
drogen-deprivation therapy, with an adverse event pro-
file that was similar to that of placebo (13).
Administration of a product for chronic diseases, such
as osteoporosis, warrants characterization of long-term
efficacy and safety outcomes. We previously reported re-
sults from a phase 2, dose-ranging trial to assess the effects
of continuous denosumab administration as compared
with placebo or alendronate through 4 yr of treatment
(14). This study was extended for an additional 4 yr to
permit continued evaluation of efficacy and safety for up
to 8 yr of continuous denosumab exposure. We report
here interim 2-yr analyses from that extension study, rep-
resenting up to 6 yr of exposure to denosumab, its longest
evaluation to date.
Subjects and Methods
The methods and entry criteria for eligibility in the 4-yr parent
phase 2 study have been published elsewhere (14–16). The fol-
lowing summarizes study methodology for the parent study and
that for the study extension.
Study design
This open-label, single-arm study extension was conducted in
23 study centers in the United States. An institutional review
board reviewed and approved the study protocol at each study
center, and the study was performed in compliance with the
World Medical Association Declaration of Helsinki principles.
All study subjects provided written informed consent.
Subjects
Postmenopausal women aged 80 yr or younger with low bone
mass were eligible for the parent study if they had a BMD T-score
between 1.8 and 4.0 for the lumbar spine or between 1.8
and 3.5 for either the total hip or femoral neck. For eligibility
in the extension study, subjects were required to have success-
fully completed the parent study, including the end-of-study visit
at month 48. Subjects were excluded if they had experienced any
of the following during the parent study: severe and/or serious
adverse events, including abnormal laboratory results, thought
to be related to denosumab; discontinued investigational prod-
uct due to protocol-specified BMD decrease during the study;
missed two or more scheduled administrations of investigational
product during yr 3 or 4; used any bone-active drugs; or devel-
oped a disease known to affect bone metabolism.
Study procedures
The baseline visit (d 1) of the study extension occurred on the
same day as that of the end-of-study visit of the parent study (yr
4  14 d). Subsequent study visits were conducted at the first
month of enrollment and every 6 months (Q6M) through yr 5
and 6. Dual-energy x-ray absorptiometry (instrument from GE
Lunar, Madison, WI, or Hologic, Waltham, MA) was used to
measure BMD at the lumbar spine (L1–L4), total hip, femoral
neck, and one third radius at study entry and yr 5 and 6. The same
machine was used for the parent and extension studies, and the
same side of the body that was measured for the total hip, femoral
neck, and one third radius was used whenever possible. Quality
control and scan analysis were conducted at Bio-Imaging Tech-
nologies Inc. (Newtown, PA).
Serum samples for measuring levels of the bone turnover
markers for C-telopeptide (CTX) and bone-specific alkaline
phosphatase (BSAP) were drawn after an overnight fast and be-
fore the next denosumab dose, and an additional draw for CTX
was performed at 1 month after dose in yr 1 and yr 5 of the parent
and extension studies. The assay for CTX was Crosslaps Nordic
Biosciences (Herlev, Denmark), with coefficient of variation of
4–13%; the assay for BSAP was Tandem-R Ostase (Hybritech
Inc., San Diego, CA) or Access Ostase assay (Beckman Coulter,
Inc. Fullerton, CA) with coefficient of variation of 3.6–6.4%. In
yr 1–4, CTX was processed at Amgen, Division of Pharmaco-
kinetics and Drug Metabolism (Thousand Oaks, CA), where the
premenopausal reference range was defined as 200–900 pg/ml.
In yr 5–6, CTX was processed by PPD (Richmond, VA), where
the premenopausal reference range was defined as 68–661 pg/
ml. For the parent and extension studies, BSAP was processed at
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Covance Laboratories (Indianapolis, IN), where the premeno-
pausal reference range was defined as 3.2–20.9 g/liter. Hema-
tology and safety serum chemistries were performed at study
entry, first month of enrollment, and Q6M in yr 5 and 6. Serum
denosumab concentrations and anti-denosumab-binding anti-
body titers were drawn at the time of serum chemistries, except
at month 18 in the study extension. Antibody evaluation used a
validated electrochemiluminescent immunoassay, and a cell-
based assay was used to screen positive samples, as previously
described (14–16).
Reports of adverse events were collected at every visit. Infor-
mation about new fractures was recorded including date, ana-
tomical site, degree of trauma involved, and treatment.
Treatment
Treatment groups in the parent and the extension studies are
depicted in Fig. 1. Subjects were instructed to take daily oral
supplemental calcium (500 mg) and vitamin D (400 IU).
Although all subjects in the extension study received denosumab
60 mg sc Q6M, they were grouped according to the treatment
regimens received during the parent study.
Continuous treatment
Subjects received denosumab for 4 yr. During the first 2 yr, the
doses were 6 mg Q3M, 14 mg Q3M, 14 mg Q6M, 60 mg Q6M,
or 100 mg Q6M. During yr 3 and 4, all subjects received 60 mg
Q6M.
Retreatment
Subjects received denosumab 30 mg Q3M for yr 1 and 2,
placebo Q6M for yr 3, and denosumab 60 mg Q6M for yr 4.
Off-treatment
Subjects received denosumab 210 mg Q6M for yr 1 and 2 and
placebo Q6M for yr 3 and 4.
Alendronate
Subjects received alendronate 70 mg once weekly for yr 1 and
2 and no treatment for yr 3 and 4.
Placebo
Subjects received placebo for 4 yr.
Statistical analyses
No hypothesis testing was performed because the primary
objective was collection of safety information; efficacy endpoints
were considered exploratory.
Descriptive statistics were used to summarize extension study
subject demographics and baseline characteristics (mean and SD
for continuous variables and frequency and percentage for cat-
egorical variables). Because this study did not have a control
group, data from the first 4 yr of the parent study (14) served as
the comparator. We report percent change in BMD at the lumbar
spine, total hip, femoral neck, and one third radius from the
parent and extension study baseline values as well as actual val-
ues of bone turnover markers from the extension study and par-
ent study baseline values. Percent changes in BMD were sum-
marized using analysis of covariance with the treatment groups
used singly or pooled as the main effect and geographical loca-
tion and the parent and extension study baseline BMD values as
covariates. The least-squares means and 95% confidence inter-
vals of percent changes from extension and parent study base-
lines in BMD over the 2- and 6-yr study courses, respectively,
were examined. Due to the skewed nature of bone turnover
marker data, median and interquartile range (first quartile to
third quartile) for actual values were examined over the 6 yr by
treatment group.
Safety analysis included subjects who received at least one
dose of denosumab. Because this study did not have a control
group, subjects were compared with subjects who had received
denosumab or placebo in yr 1–4.
FIG. 1. Study design of the 4-yr parent dose-ranging study showing the initial treatment regimens and changes in treatment that occurred at
months 24, 36, and 48 and the 2-yr extension study in which all subjects received denosumab 60 mg Q6M. QW, Every week.
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Results
Patients
This 2-yr interim report provided information from
May 23, 2006 (first subject enrolled), to May 19, 2009
(last subject completed yr-6 study visit). Of the 200 sub-
jects who entered the extension study, which represented
yr 5, 178 (89%) completed the 6-yr assessment (Fig. 1).
Baseline demographics for the cohort have been reported
elsewhere (14–16). Review of demographics at study ex-
tension entry revealed an older cohort, reflecting 4 yr that
had passed since enrollment in the parent study (Table
1). Also of note, BMD T-scores at the lumbar spine,
total hip, femoral neck, and one third radius were higher
compared with their baseline demographics in the par-
ent study, reflecting treatment interventions in the an-
tecedent 4 yr (Table 1).
Efficacy assessments
Continuous treatment cohort
In the continuous treatment group, 2 additional years
of denosumab treatment led to further gains in BMD.
From the extension study baseline, mean BMD increased
at the lumbar spine by 2.9% (Fig. 2A), total hip by 1.1%
(Fig. 2B), one third radius by 1.0% (Fig. 2C), and femoral
neck by 1.2% (data not shown). Six years of continuous
treatment was associated with mean BMD changes from
parent study baseline of 13.3, 6.1, and 1.9% for the lum-
bar spine, total hip, and one third radius, respectively (Fig.
2), and 5.6% for femoral neck (data not shown). At yr 6,
serum CTX remained below parent study baseline with a
median reduction of 54.8% compared with baseline (Fig.
3). The level of reduction in CTX was similar through all
measured time points in the study extension when CTX
was measured at the end of the dose interval. To charac-
terize the effects of short- and long-term denosumab ad-
ministration on the magnitude of reduction in CTX, we
compared CTX values 1 month after dose in yr 1 and 5,
which showed median reductions of 89.3 and 91.2%, re-
spectively, compared with parent study baseline (Fig. 4).
Median reductions in CTX 6 months after dose for these
intervals were 72.1% in yr 1 and 47.5% in yr 5 (Fig. 4).
Retreatment, off-treatment, alendronate, and
placebo cohorts
These cohorts had exposure or reexposure to deno-
sumab for 2 yr in the study extension. Regardless of pre-
vious pharmacological exposure, these four treatment
groups similarly showed gains in BMD at the lumbar
spine, total hip, one third radius (Fig. 2), and femoral neck
(data not shown). All subjects responded to denosumab
with reductions in CTX and BSAP, independent of previ-
ous treatment assignments (Fig. 5). Both bone turnover
markers remained within the premenopausal reference
range when measured in the study extension.
Safety evaluations (Table 2)
All 200 subjects in the study extension 2-yr interim
analysis received at least one dose of denosumab, and 176
subjects (88%) received all four doses of denosumab. Be-
cause the study did not have a control group, incidence
rates of adverse events were compared with those of sub-
jects who received denosumab or placebo in the first 4 yr
of the study.
One hundred sixty-six subjects (83.0%) reported at
least one adverse event. The three most frequent adverse
events were upper respiratory infection (13.5%), arthral-
gia (11.5%), and back pain (9.0%), findings that were
consistent with what has been reported during the previ-
ous 4 yr of treatment (Table 2). No other adverse events
occurred with an incidence of at least 10% in subjects
enrolled in the extension study. To provide comparative
incidence, adverse events that were reported as at least
10% in yr 1–4 are provided in Table 2 along with rates
reported during 2 yr of the study extension. Five subjects
(2.5%) reported adverse events of eczema (four subjects
with contact dermatitis and one with eczema). Two sub-
jects (1.0%) had skin infection (one case of skin bacterial
TABLE 1. Subject demographics and characteristics at baseline in parent and extension studies







Age (yr) 62.5 (8.1) 62.3 (8.0) 66.1 (7.7)
Time since menopause (yr) 16.2 (9.9) 16.5 (9.8) 19.3 (9.1)
Lumbar spine BMD T-score 2.14 (0.78) 2.14 (0.77) 1.55 (0.96)
Total hip BMD T-score 1.44 (0.71) 1.42 (0.69) 1.21 (0.73)
Femoral neck BMD T-score 1.87 (0.67) 1.86 (0.68) 1.68 (0.70)
One third radius BMD T-score 1.48 (1.21) 1.48 (1.18) 1.35 (1.19)
Subjects who completed n (%) 262 (64) 203 (64) 178 (89)
Values are mean (SD) unless indicated otherwise.
a Values from parent study (14–16).
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infection and staphylococcal infection and one case of skin
infection).
Twenty-six subjects (13.0%) experienced an adverse
event that was categorized as serious (Table 2). Neoplasms
were reported in 3.5% of subjects in the extension study:
one subject was diagnosed with liver, bone, and lung met-
astatic disease (unknown primary), one with breast cancer
in situ, one with breast cancer, one with benign gastroin-
testinal neoplasm, two with lung neoplasms, and one with
colon cancer. Three infections associated with hospital-
ization were reported: one case of pneumonia, one case of
endocarditis and staphylococcal bacteremia, and one case
of diverticulitis (Table 2). Three subjects died during the
extension study: one from an unknown cause, 1 from a
FIG. 4. Comparison of equivalent dosing intervals at 1 and 6 months
after dose for serum CTX in yr 1 and 5. Box plots of CTX actual values
are shown. The horizontal dashed lines represent the premenopausal
ranges.
FIG. 2. Effect of 6 yr of denosumab treatment on BMD at the lumbar
spine (A), total hip (B), and one third radius (C). BMD values are shown
as percent change from parent study baseline [least square mean
(LSM)  95% confidence interval (CI)]. The vertical dashed lines at
months 24 and 48 indicate changes in dosing regimens. Gray boxes
indicate the original 4-yr parent study.
FIG. 3. Effect of 6 yr of continuous denosumab treatment on levels of
CTX (A) and BSAP (B). Bone turnover markers are shown as actual
values [median with Q1–Q3 interquartile range (IQR)]. The horizontal
dashed lines represent the premenopausal ranges, and the vertical
dashed lines at months 24 and 48 indicate changes in dosing
regimens. Gray boxes indicate the original 4-yr parent study.
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hepatic malignant neoplasm, and 1 from chronic obstruc-
tive pulmonary disease. No case of osteonecrosis of the
jaw was reported.
Nine subjects (4.5%) sustained at least one fracture
during the extension study; the fractures included fibula,
foot, rib, humerus, hand, radius, thoracic vertebra, and
tibia (Table 2). There were no reports of delayed fracture
healing or fracture nonunion.
No clinically relevant changes in blood chemistries
were observed. Although three subjects experienced ad-
verse events considered potential clinical manifestations
of hypocalcemia, including paraesthesia (1) and hypoaes-
thesia (2), no symptoms of hypocalcemia were reported by
the investigators. Mean calcium change from parent study
baseline was less than or equal to 0.1 mmol/liter for all
treatment groups. No subject developed antibodies to de-
nosumab during the extension study.
Discussion
This ongoing study, which was initiated in 2002 and be-
gan as a 12-month, phase 2 dose-ranging trial, represents
6 yr of treatment with denosumab, the longest reported
clinical experience to date. Phase 2 studies do not require
large sample sizes because they are designed to identify
optimal dose of investigational product to evaluate in fu-
ture populations. Nevertheless, important efficacy and
safety information may be gleaned from these study sub-
jects (17–20).
In this study extension, gains in BMD were observed for
all treated cohorts. For subjects in the continuous treat-
ment cohort, 2 additional years of denosumab treatment
led to further gains in BMD. In the other treatment co-
horts, subjects with longer duration of prior treatment had
smaller gains compared with those who had had shorter
prior treatment. Continued BMD accrual over 6 yr, with-
out evidence of plateau, raises the question as to the mech-
anism by which this finding occurs. One hypothesis is that
denosumab, like alendronate, closes the remodeling space
and prolongs remodeling with increased mineralization
over time (18). Another hypothesis is that denosumab,
when compared with alendronate, causes greater reduc-
tion in bone resorption and longer remodeling time (21),
independent of bone surface available for remodeling,
leading to fewer new bone modeling units and concurrent
filling in of preexisting resorption cavities (22). A third
hypothesis is that the increase in CTX observed at the end
of the dosing interval with denosumab permits some de-
gree of remodeling, and the newly formed bone subse-
quently mineralizes after the next denosumab dose. Our
comparison of short- and long-term effects of continuous
denosumab administration showed consistent postdose
CTX reduction with quantitative CTX increases at the end
of the dosing interval. This active profile of serum CTX
with denosumab differs from that of alendronate and
other bisphosphonate therapies, where a steady state of
reduction in bone resorption persists with continued ad-
ministration (23, 24).
The mechanism for the attenuation in CTX reduction
at the end of the dosing interval over time is not fully
understood. The bone mechanostat concept suggests that
skeletons, even those with low bone mass, appear to pos-
sess a bone remodeling set point that might be genetically
determined (25, 26). The bone mechanostat concept hy-
pothesizes that each individual has a preset level of bone
remodeling and density that is influenced by a variety of
genetic and biomechanical stressors on the skeleton. The
gradual rise in CTX over time with continuous deno-
sumab exposure may reflect discrete changes in the degree
of RANKL expression as a consequence of the mechano-
stat. Further investigation is required to test such a hy-
pothesis. Development of tolerance to denosumab is
unlikely for two reasons: 1) significant reductions in
FIG. 5. Effect of bone turnover marker level of CTX (A) and BSAP (B)
in the antecedent off-treatment, retreatment, and alendronate
treatment groups over 6 yr. Bone turnover markers are shown as
actual values [median with Q1–Q3 interquartile range (IQR)]. The
horizontal dashed lines represent the premenopausal ranges, and the
vertical dashed lines at months 24 and 48 indicate changes in dosing
regimens. Gray boxes indicate the original 4-yr parent study.
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CTX at 1 month after dose were consistent in yr 1 and
5 and 2) CTX levels at the end of the dosing interval
were consistently reduced with long-term administra-
tion, as evidenced in yr 4 – 6. These observations suggest
a durable response to denosumab with long-term
administration.
This study also provides insights into the safety of long-
term exposure, where subjects received up to 16 doses of
denosumab over 6 yr. No subjects developed neutralizing
antibodies to denosumab, demonstrating that there was
no evidence of long-term immunogenicity. Reported ad-
verse events were generally mild to moderate in severity
and consistent with past reports in yr 1–4 of exposure in
this study. There was no discernible pattern of the tem-
poral relationship of the events to investigational product
administration, and there was no evidence of increased
frequency of a specific event over time. Fracture incidence
over time was constant, and there was no evidence of de-
layed healing. Review of infections during the 2-yr exten-
sion was similar to what was observed during the first 4 yr
of the study, and there were no cases of opportunistic
infections or deaths related to infection. Despite the rela-
tively small sample size in this study, these data provide
early information about the safety of denosumab for up to
6 yr of exposure. These data will be expanded upon
through a 7-yr study extension to the denosumab pivotal
fracture trial, which will provide 10 yr of data regarding
long-term efficacy and safety in a larger population of
postmenopausal women with osteoporosis.
In conclusion, continuous treatment with denosumab
resulted in sustained reduction in bone turnover markers
and further gains in BMD over a period of up to 6 yr in
postmenopausal women with low bone mass. Indepen-
dent of past treatment and discontinuation period, sub-
jects demonstrated responsiveness when treated with de-
nosumab therapy, as measured by BMD and bone
turnover markers. The overall safety profile in this ongo-
ing study extension did not change over time; denosumab
was well tolerated and effective through 6 yr of continuous
treatment.
TABLE 2. Adverse event summary








Any adverse event 93.5 (43) 93.3 (293) 83.0 (166)
Infections 67.4 (31) 66.2 (208) 40.0 (80)
Fractures 10.9 (5) 10.5 (33) 4.5 (9)
Serious adverse events 10.9 (5) 17.8 (56) 13.0 (26)
Hospitalized infections 0.0 (0) 3.2 (10) 1.5 (3)
Neoplasms 4.3 (2) 4.8 (15) 3.5 (7)
Treatment-related adverse events 21.7 (10) 20.4 (64) 10.0 (20)
Serious treatment-related adverse events 0.0 (0) 1.3 (4) 1.0 (2)
Withdrawals due to adverse event 4.3 (2) 4.5 (14) 4.0 (8)
Deaths 0.0 (0) 1.3 (4) 1.5 (3)
Adverse events occurring in 10 of subjects
in any treatment group % (n)
Upper respiratory infection 23.9 (11) 28.0 (88) 13.5 (27)
Arthralgia 30.4 (14) 23.6 (74) 11.5 (23)
Back pain 13.0 (6) 20.1 (63) 9.0 (18)
Nasopharyngitis 15.2 (7) 19.1 (60) 3.0 (6)
Pain in extremity 17.4 (8) 17.5 (55) 5.0 (10)
Hypertension 4.3 (2) 15.3 (48) 6.5 (13)
Influenza-like illness 10.9 (5) 13.1 (41) 1.0 (2)
Urinary tract infection 4.3 (2) 13.1 (41) 5.5 (11)
Gastroesophageal reflux disease 4.3 (2) 12.7 (40) 3.5 (7)
Dyspepsia 6.5 (3) 12.4 (39) 2.5 (5)
Headache 17.4 (8) 12.1 (38) 3.0 (6)
Nausea 4.3 (2) 12.1 (38) 1.5 (3)
Sinusitis 19.6 (9) 11.8 (37) 7.0 (14)
Muscle spasms 15.2 (7) 10.2 (32) 5.5 (11)
Musculoskeletal pain 15.2 (7) 9.6 (30) 4.5 (9)
Diarrhea 13.0 (6) 8.9 (28) 3.0 (6)
Bronchitis 10.9 (5) 8.3 (26) 3.0 (6)
Peripheral edema 10.9 (5) 4.8 (15) 3.0 (6)
N  all subjects who received at least one dose of study drug; n  number of subjects reporting at least one event.
a Values from parent study (14–16).
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